This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Patency Period of the New Plastic Anti-reflux Biliary Stent

This study has been terminated.
(Issue regarding the stent design)
Sponsor:
Information provided by (Responsible Party):
James Yun-wong Lau, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT01142921
First received: June 8, 2010
Last updated: April 20, 2017
Last verified: April 2017
  Purpose
The aim of this study is to determine the average patency period of the new anti-reflux biliary stent on patients with malignant bile duct strictures and to determine if this stent remains patent for a longer period of time comparing with the ordinary plastic Tannenbaum biliary stent.

Condition Intervention
Pancreatitis Cholangitis Device: Anti-reflux Tannenbaum biliary stent Device: Ordinary Tannenbaum biliary stent

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
Official Title: A Prospective Randomised Study on the Patency Period of the Plastic Anti-reflux Biliary Stent

Resource links provided by NLM:


Further study details as provided by James Yun-wong Lau, Chinese University of Hong Kong:

Primary Outcome Measures:
  • time-to-occlusion or stent patency period in days [ Time Frame: within 25 weeks of device application ]

Secondary Outcome Measures:
  • Bleeding associated with endoscopic retrograde cholangiopancreatography (ERCP) and stent placement [ Time Frame: within 25 weeks of device application ]
  • perforation associated with ERCP and stent placement [ Time Frame: within 25 weeks of device application ]
  • pancreatitis associated with ERCP and stent placement [ Time Frame: within 25 weeks of device application ]
  • cholangitis associated with ERCP and stent placement [ Time Frame: within 25 weeks of device application ]
  • stent migration associated with ERCP and stent placement [ Time Frame: within 25 weeks of device application ]
  • all cause mortality [ Time Frame: within 25 weeks of device application ]

Enrollment: 16
Actual Study Start Date: November 2008
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ordinary Tannenbaum biliary stent
Ordinary Tannenbaum biliary stent
Device: Ordinary Tannenbaum biliary stent
Ordinary Tannenbaum biliary stent
Other Name: ST-2 Soehendra® Tannenbaum® Biliary Stent
Experimental: Anti-reflux Tannenbaum biliary stent
Anti-reflux Tannenbaum biliary stent
Device: Anti-reflux Tannenbaum biliary stent
Anti-reflux Tannenbaum biliary stent
Other Name: Fusion® Marathon™ Anti-Reflux Biliary Stent

Detailed Description:

Bile duct related cancer is a condition quite commonly seen among Asians. Predisposing conditions for primary bile duct cancer include recurrent infections and autoimmune diseases such as recurrent pyogenic cholangitis (RPC) and primary sclerosing cholangitis (PSC) as well as congenital problem such as choledochal cyst. Peri-ampullary tumour, pancreatic tumour and metastatic tumours with bile duct compression are other causes of bile duct obstruction. As many of these tumours are discovered at a late stage, curative treatment is usually not feasible. Palliative endoscopic stenting of the obstructed biliary system remains the treatment of choice for the majority.

The main problem with endoscopic stenting of the biliary system is the short stent patency period. There are some reports on modifications to plastic biliary stenting method in recent years including changes in stent designs, use of a different material or coating, administrating prophylactic antibiotics and the use of special drugs. All these have failed to show any conclusive effect on the stent patency period.

A preliminary study has demonstrated some promising results in the use of a stent with an anti-reflux property very similar to the stents the investigators are using in this study.

  Eligibility

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years old
  • Patients who have cholangiographic evidence (on ERCP) consistent with a malignant extrahepatic biliary stricture (below bifurcation of the common hepatic duct) who require plastic stenting
  • Patients with peri-ampullary tumours, pancreatic tumours, gall bladder cancer and metastatic tumours with suspected extrinsic bile duct compression
  • Patients with stent or nasobiliary drain in-situ without previous sphincterotomy will qualify for the study if they satisfy the above inclusion criteria.

Exclusion Criteria:

  • Patients fit for surgery.
  • Patients who have dominant biliary strictures involving the hilum or more proximal biliary segments.
  • Previous sphincterotomy.
  • Other medical conditions that will result in a life expectancy of less then 3 months (ASA class >4)
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01142921

Locations
China
Endoscopy Centre
Hong Kong, China
Sponsors and Collaborators
Chinese University of Hong Kong
Investigators
Principal Investigator: Wai L Quan, Dr. Chinese University of Hong Kong
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: James Yun-wong Lau, Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT01142921     History of Changes
Other Study ID Numbers: ARBS
Study First Received: June 8, 2010
Last Updated: April 20, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by James Yun-wong Lau, Chinese University of Hong Kong:
Stent Occlusion
Biliary Bleeding
Biliary Perforation

Additional relevant MeSH terms:
Pancreatitis
Cholangitis
Pancreatic Diseases
Digestive System Diseases
Bile Duct Diseases
Biliary Tract Diseases

ClinicalTrials.gov processed this record on June 23, 2017